Skip to main
CYRX

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. demonstrated robust financial growth with a total revenue of $44 million, reflecting a 15% increase in constant currency terms, which shows an uptick from the previous quarter's 14% growth. The ongoing rise in gene therapy programs, particularly in oncology and rare diseases, supports a favorable outlook as the market becomes increasingly receptive to innovative cell and gene therapies. The anticipated increase in both commercial revenue and clinical trial activity indicates a stable growth trajectory, reinforcing positive sentiment around the company's future prospects.

Bears say

CryoPort Inc. faces a challenging outlook as revenue growth in its Life Sciences Services segment has slowed, with a 16% increase in the latest quarter, down from 21% in the previous quarter, indicating potential long-term declining trends. The company's adjusted EBITDA margin remains in negative territory at (1.5%), which, despite an annual improvement, fell short of market expectations, further suggesting potential profitability issues. Additionally, the bear case scenarios highlight concerns over slowing demand for critical products and a decline in the approval of cell and gene therapies, which may adversely impact future growth and margins.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.